Patents by Inventor Jeongwon Sohn

Jeongwon Sohn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of expanding NK cell and composition for culturing
    Patent number: 11110126
    Abstract: Provided are a method of ex-vivo culture of natural killer (NK) cells by treating the cells with a reactive oxygen species (ROS) inhibitor and/or a p53 protein inhibitor; and a composition comprising the cultured NK cells. By reducing the activity of ROS and p53 proteins during ex-vivo culture, NK cells may have achieved greater expansion efficiency without altering their anti-tumor cytotoxicity.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: September 7, 2021
    Assignee: Korea University Research and Business Foundation
    Inventors: Kyung-Mi Lee, Jeongwon Sohn, Seon Ah Lim, Jang-Mi Lim
  • METHOD OF EXPANDING NK CELL AND COMPOSITION FOR CULTURING
    Publication number: 20190183995
    Abstract: Provided are a method of ex-vivo culture of natural killer (NK) cells by treating the cells with a reactive oxygen species (ROS) inhibitor and/or a p53 protein inhibitor; and a composition comprising the cultured NK cells. By reducing the activity of ROS and p53 proteins during ex-vivo culture, NK cells may have achieved greater expansion efficiency without altering their anti-tumor cytotoxicity.
    Type: Application
    Filed: February 21, 2019
    Publication date: June 20, 2019
    Applicant: Korea University Research and Business Foundation
    Inventors: Kyung-Mi Lee, Jeongwon Sohn, Seon Ah Lim, Jang-Mi Lim
  • METHOD OF EXPANDING NK CELL AND COMPOSITION FOR CULTURING
    Publication number: 20170119865
    Abstract: Provided are a method of ex-vivo culture of natural killer (NK) cells by treating the cells with a reactive oxygen species (ROS) inhibitor and/or a p53 protein inhibitor; and a composition comprising the cultured NK cells. By reducing the activity of ROS and p53 proteins during ex-vivo culture, NK cells may have achieved greater expansion efficiency without altering their anti-tumor cytotoxicity.
    Type: Application
    Filed: July 7, 2016
    Publication date: May 4, 2017
    Applicant: Korea University Research and Business Foundation
    Inventors: Kyung-Mi Lee, Jeongwon Sohn, Seon Ah Lim, Jang-Mi Lim